Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Sana Biotechnology Inc — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $28.56, while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). Which is the better fit depends on your goals.
| KOLD | SANA | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $5.92 |
52-Week Low | $13.58 | $2.68 |
Market Cap | — | $1.13B |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD trades at $28.54, down 0.35% on the day, with technical indicators showing a bullish bias from moving averages while oscillators remain neutral. The ETF tracks natural gas price movements inversely, with recent news highlighting volatility in natural gas markets driven by weather patterns and LNG demand. Support levels cluster around $28 with resistance at $29-$30.
As a leveraged ETF, KOLD carries significant volatility risks and is designed for short-term trading rather than long-term investment. The natural gas market faces headwinds from production levels and storage data, while geopolitical developments and weather patterns create trading opportunities for tactical investors.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
